ALKS

SEC source: 0001127602-24-004630 · form4.xml · derivative · entry 8

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,413

Underlying: Ordinary Shares · 3,929 shares

Expires 2031-02-22

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-004630 · form4.xml · derivative · entry 7

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,297

Underlying: Ordinary Shares · 201 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-004630 · form4.xml · derivative · entry 6

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,232

Underlying: Ordinary Shares · 3,376 shares

Expires 2030-02-20

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-004630 · form4.xml · derivative · entry 5

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,833

Underlying: Ordinary Shares · 2,133 shares

Expires 2029-02-21

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004630 · form4.xml · derivative · entry 4

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,589

Underlying: Ordinary Shares · 1,089 shares

Expires 2028-02-16

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004630 · form4.xml · derivative · entry 3

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,599

Underlying: Ordinary Shares · 1,599 shares

Expires 2027-06-07

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 18

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,757

Underlying: Ordinary Shares · 603 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F14 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F14 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 17

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,027

Underlying: Ordinary Shares · 2,412 shares

Expires 2033-02-23

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F13 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 16

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,043

Underlying: Ordinary Shares · 118 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F12 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 8/3/2023.

F12 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 8/3/2023.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 15

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,388

Underlying: Ordinary Shares · 576 shares

Expires 2032-08-03

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F11 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 8/3/2023.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 14

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,064

Underlying: Ordinary Shares · 373 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F10 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F10 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 13

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,674

Underlying: Ordinary Shares · 1,992 shares

Expires 2032-02-18

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F9 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 12

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,863

Underlying: Ordinary Shares · 291 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 11

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,303

Underlying: Ordinary Shares · 2,378 shares

Expires 2031-02-22

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 10

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,177

Underlying: Ordinary Shares · 140 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 9

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,040

Underlying: Ordinary Shares · 2,352 shares

Expires 2030-02-20

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 8

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,833

Underlying: Ordinary Shares · 2,133 shares

Expires 2029-02-21

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 7

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,589

Underlying: Ordinary Shares · 1,089 shares

Expires 2028-02-16

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 6

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,799

Underlying: Ordinary Shares · 799 shares

Expires 2027-02-17

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 5

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,719

Underlying: Ordinary Shares · 719 shares

Expires 2026-02-28

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 4

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,104

Underlying: Ordinary Shares · 354 shares

Expires 2025-02-26

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004629 · form4.xml · derivative · entry 3

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,499

Underlying: Ordinary Shares · 499 shares

Expires 2024-03-03

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 16

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,300

Underlying: Ordinary Shares · 456 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F12 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F12 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 15

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,202

Underlying: Ordinary Shares · 1,827 shares

Expires 2033-02-23

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F11 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 14

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,064

Underlying: Ordinary Shares · 373 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F10 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F10 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 13

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,674

Underlying: Ordinary Shares · 1,992 shares

Expires 2032-02-18

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F9 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 12

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,217

Underlying: Ordinary Shares · 278 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 11

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,028

Underlying: Ordinary Shares · 2,274 shares

Expires 2031-02-22

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 10

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,680

Underlying: Ordinary Shares · 91 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 9

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,287

Underlying: Ordinary Shares · 1,534 shares

Expires 2030-02-20

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 8

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,989

Underlying: Ordinary Shares · 1,489 shares

Expires 2029-02-21

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 7

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,759

Underlying: Ordinary Shares · 759 shares

Expires 2028-02-16

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 6

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,799

Underlying: Ordinary Shares · 799 shares

Expires 2027-02-17

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 5

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,719

Underlying: Ordinary Shares · 719 shares

Expires 2026-02-28

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 4

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,104

Underlying: Ordinary Shares · 354 shares

Expires 2025-02-26

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004628 · form4.xml · derivative · entry 3

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,499

Underlying: Ordinary Shares · 499 shares

Expires 2024-03-03

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004741 · form4.xml · derivative · entry 10

MCKEON BRIAN P · CIK 0001219445 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-004741 · form4.xml · derivative · entry 9

MCKEON BRIAN P · CIK 0001219445 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001127602-24-004741 · form4.xml · derivative · entry 8

MCKEON BRIAN P · CIK 0001219445 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004741 · form4.xml · derivative · entry 7

MCKEON BRIAN P · CIK 0001219445 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,990

Underlying: Ordinary Shares · 313 shares

Expires 2031-06-14

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004741 · form4.xml · derivative · entry 6

MCKEON BRIAN P · CIK 0001219445 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,533

Underlying: Ordinary Shares · 88 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F5 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-24-004741 · form4.xml · derivative · entry 5

MCKEON BRIAN P · CIK 0001219445 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,692

Underlying: Ordinary Shares · 523 shares

Expires 2031-02-10

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004741 · form4.xml · derivative · entry 4

MCKEON BRIAN P · CIK 0001219445 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,639

Underlying: Ordinary Shares · 90 shares

Expires 2031-02-10

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004738 · form4.xml · derivative · entry 10

Daglio David Angelo Jr. · CIK 0001837109 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-004738 · form4.xml · derivative · entry 9

Daglio David Angelo Jr. · CIK 0001837109 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001127602-24-004738 · form4.xml · derivative · entry 8

Daglio David Angelo Jr. · CIK 0001837109 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004738 · form4.xml · derivative · entry 7

Daglio David Angelo Jr. · CIK 0001837109 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,990

Underlying: Ordinary Shares · 313 shares

Expires 2031-06-14

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004738 · form4.xml · derivative · entry 6

Daglio David Angelo Jr. · CIK 0001837109 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,533

Underlying: Ordinary Shares · 88 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F5 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-24-004738 · form4.xml · derivative · entry 5

Daglio David Angelo Jr. · CIK 0001837109 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,692

Underlying: Ordinary Shares · 523 shares

Expires 2031-02-10

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004738 · form4.xml · derivative · entry 4

Daglio David Angelo Jr. · CIK 0001837109 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,639

Underlying: Ordinary Shares · 90 shares

Expires 2031-02-10

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.